cas 261945-75-9|| where to buy 1-bromo-2,5-difluoro-4-(trifluoromethyl)benzene

Nom du produit:1-bromo-2,5-difluoro-4-(trifluoromethyl)benzene

IUPAC Name:1-bromo-2,5-difluoro-4-(trifluoromethyl)benzene

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM329502-250mg	in stock	ǆȦ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 261945-75-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:261945-75-9; Formule moléculaire:C7H2BrF5; Point de fusion:-; Code SMILES:FC(C1=C(F)C=C(Br)C(F)=C1)(F)F; Densité:

: Numéro de catalogue:CM329502; Poids moléculaire:260.99; Point d'ébullition:; N° Mdl:; Stockage:

: Nelutroctiv; The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility”. Heart failure (HF) is a lifelong clinical syndrome and remains a major societal concern. Cardiac myosin activators constitute a new class of inotropes and are found to be a viable therapeutic approach for increasing myocardial contractility.
CK-136 is a small molecule cardiac troponin activator that is discovered under a previous joint research program between Cytokinetics and Amgen. It acts on the sarcomere and is designed to improve myocardial contractility by sensitizing cardiac troponin to calcium, increasing actin-myosin cross bridge formation during each cardiac cycle. CK-136 is developed as a potential treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and other types of heart failure, and currently under phase 1 clinical investigation.